Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT2A receptor antagonist. It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease and as of February 2012 is in phase IIb clinical trials.
This page contains content from the copyrighted Wikipedia article "Iferanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.